#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
I don’t see a summary provided in your request. To write clinicians-relevant sentences about this article, I would need the summary content to understand the specific findings about cannabinoid hyperemesis syndrome (scromiting) and its clinical implications. Could you provide the article summary so I can generate the appropriate response?
Cannabinoid hyperemesis syndrome (CHS), colloquially termed “scromiting” due to the violent screaming and vomiting it produces, is an increasingly recognized condition among chronic cannabis users that presents clinicians with a diagnostic challenge. The syndrome typically occurs in heavy, long-term cannabis consumers and is characterized by cyclic episodes of severe nausea, vomiting, and abdominal pain, often accompanied by compulsive hot bathing that temporarily relieves symptoms. Current understanding suggests that while cannabinoids provide symptomatic relief in acute episodes, the underlying pathophysiology remains incompletely characterized, though dysregulation of the endocannabinoid system and transient receptor potential channels have been proposed mechanisms. Recognition of CHS is critical for clinicians because affected patients often undergo extensive gastrointestinal workup and receive ineffective treatments before the diagnosis is established, leading to unnecessary healthcare utilization and delayed resolution through cannabis cessation. The rise in CHS cases directly correlates with increased cannabis potency and frequency of use in the population, particularly with concentrated products and daily consumption patterns. Clinicians should maintain a high index of suspicion for CHS in patients presenting with refractory cyclic vomiting, especially those reporting heavy cannabis use, as early recognition and counseling on cessation offer the most effective therapeutic pathway.
“Cannabinoid hyperemesis syndrome is a real clinical entity I see with increasing frequency in heavy daily users, and the cyclical vomiting pattern we call scromiting represents a genuine cannabinoid toxicity threshold that our patients need to understand before they assume more cannabis means better symptom management. The mechanism isn’t fully elucidated, but the clinical presentation is consistent and reproducible, and the only reliable treatment remains cessation, which tells us we need to counsel patients on dose and frequency limits just as rigorously as we do with any other medicine.”
💊 Cannabinoid Hyperemesis Syndrome (CHS), colloquially termed “scromiting” due to the combination of screaming and vomiting, represents an increasingly recognized but still poorly understood adverse effect in chronic high-potency cannabis users. While the syndrome’s pathophysiology remains incompletely characterized, emerging clinical and epidemiological data suggest it may be more prevalent than previously appreciated, particularly as cannabis products have become more potent and accessible. Clinicians should maintain a high index of suspicion for CHS in patients with recurrent, refractory nausea and vomiting, especially those with concurrent cannabis use, though the diagnosis remains clinical and no biomarkers currently exist. A key diagnostic challenge is that patients often continue cannabis use despite symptom onset, sometimes believing the drug alleviates rather than causes their symptoms, complicating the history and potentially delaying appropriate management. From a practical standpoint, healthcare providers
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
